PMID- 17852810
OWN - NLM
STAT- MEDLINE
DCOM- 20080124
LR  - 20131121
IS  - 0036-5513 (Print)
IS  - 0036-5513 (Linking)
VI  - 67
IP  - 7
DP  - 2007
TI  - Experimental hyperhomocysteinemia disturbs bone metabolism in rats.
PG  - 748-56
AB  - OBJECTIVE: To investigate whether experimental hyperhomocysteinemia (HHCY) can 
      induce adverse changes in bone metabolism. METHODS: Blood and urine samples were 
      collected from rats fed with a methionine-enriched diet (HHCY, n = 18) or an 
      isocaloric control diet (control, n = 10) for 12 weeks. Biochemical bone turnover 
      markers (osteocalcin, hydroxyproline, N-terminal collagen I telopeptides and 
      homocysteine (HCY), folate and vitamin B12) were measured. Whole body bone 
      mineral density (BMD) was assessed by dual energy X-ray absorptiometry. RESULTS: 
      HCY was significantly higher in HHCY than in control rats (16.2 versus 3.2 
      micromol/L; p = 0.0006). Bone resorption parameters hydroxyproline (1.60 +/- 0.6 
      versus 0.85 +/- 0.4; p<0.05) and N-terminal collagen I telopeptides (150.8 +/- 78 
      versus 48.1 +/- 26 nmol/L BCE; p<0.05) increased, whereas bone formation marker 
      osteocalcin (9.01 +/- 3.8 versus 15.07 +/- 4.2 ng/mL; p<0.05) decreased in HHCY 
      compared to control rats. The relation N-terminal collagen I 
      telopeptides/osteocalcin significantly increased in HHCY compared to control rats 
      (13.14 +/- 3.1 versus 4.14 +/- 1.9). BMD measurement did not reveal any 
      differences between groups. CONCLUSION: These findings demonstrate a significant 
      modification of bone turnover in HHCY rats. The relation between bone resorption 
      and formation indicates a shift toward bone resorption, which might be a 
      plausible explanation for the relation between HHCY and fracture risk.
FAU - Ozdem, S
AU  - Ozdem S
AD  - Medical Faculty, Central Laboratory Biochemistry Unit, Akdeniz University, 
      Antalya, Turkey. ozdem@akdeniz.edu.tr
FAU - Samanci, S
AU  - Samanci S
FAU - Tasatargil, A
AU  - Tasatargil A
FAU - Yildiz, A
AU  - Yildiz A
FAU - Sadan, G
AU  - Sadan G
FAU - Donmez, L
AU  - Donmez L
FAU - Herrmann, M
AU  - Herrmann M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Scand J Clin Lab Invest
JT  - Scandinavian journal of clinical and laboratory investigation
JID - 0404375
RN  - 0 (Collagen Type I)
RN  - 0 (Peptides)
RN  - 0 (collagen type I trimeric cross-linked peptide)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 104982-03-8 (Osteocalcin)
RN  - 935E97BOY8 (Folic Acid)
RN  - AE28F7PNPL (Methionine)
RN  - MU72812GK0 (Creatine)
RN  - P6YC3EG204 (Vitamin B 12)
RN  - RMB44WO89X (Hydroxyproline)
SB  - IM
MH  - Animals
MH  - Body Weight
MH  - Bone Density
MH  - Bone Resorption/etiology/metabolism
MH  - Bone and Bones/*metabolism
MH  - Collagen Type I/urine
MH  - Creatine/urine
MH  - Female
MH  - Folic Acid/blood
MH  - Homocysteine/blood
MH  - Hydroxyproline/urine
MH  - Hyperhomocysteinemia/chemically induced/complications/*physiopathology
MH  - Methionine/administration & dosage/blood
MH  - Osteocalcin/blood
MH  - Osteogenesis/physiology
MH  - Peptides/urine
MH  - Rats
MH  - Rats, Wistar
MH  - Vitamin B 12/blood
EDAT- 2007/09/14 09:00
MHDA- 2008/01/25 09:00
CRDT- 2007/09/14 09:00
PHST- 2007/09/14 09:00 [pubmed]
PHST- 2008/01/25 09:00 [medline]
PHST- 2007/09/14 09:00 [entrez]
AID - 777589836 [pii]
AID - 10.1080/00365510701342088 [doi]
PST - ppublish
SO  - Scand J Clin Lab Invest. 2007;67(7):748-56. doi: 10.1080/00365510701342088.